Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Alectinib

1

XIX.a BAL: An excess proportion of lymphocytes

1
Last update : 12/01/2020
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
Journal of medical case reports 2022 Aug 24;16;316 2022 Aug 24
Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Japanese journal of clinical oncology 2015 Feb;45;221-4 2015 Feb

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies